



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

Basics of design and layout development for parenteral facilities including pros and cons for advanced containment

Narendra Prasad - Director – Technical
NNE Pharmaplan India Limited

ISPE Hyderabad Chapter
08th November, 2013


ENGINEERING PHARMACEUTICAL INNOVATION



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

Thanks

for support & Guidance



Hartmut Schaz
NNE Pharmaplan
GERMANY

Phone: +49 - (0)6172 – 850 – 2663
Email: hmus@nnepharmaplan.com

ENGINEERING PHARMACEUTICAL INNOVATION



Before we begin...

1. Growing Market:

There will be higher demand of small volume parenteral facilities since the market share of biopharmaceutical products will continuously increase in the future

2. Decreasing Batch Sizes:

Due to better diagnostic methods, the number and size of blockbuster products ("one size fits all") will decrease which will require a higher flexibility for the production facilities

3. Shifting of Production Capacities:

Globally, the market will disproportionately increase in countries like Brazil, Russia, India and China (BRIC) and other countries like South Korea or Taiwan

Contents

1. Building / Process Utilities

- Flexibility
- Personnel and material flow excellence
- Working condition excellence
- Green technology
- Modular facilities

2. Process Technology

- Cleanroom technology
- Ready to fill (RTF) primary containers
- Single Use Components

3. Some conclusions

1. Building & Process Utilities -- Flexibility



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

1. Building concept to allow max. freedom for future expansion of the production functions and required support functions and technical areas
2. Design to allow remodelling of areas while production is continuing within adjacent production areas
3. Design to allow easy building expansion while production is continuing within adjacent production areas

ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013


ISPE VIZAG PROGRAMME

5 of 44

1. Building & Process Utilities -- Flexibility



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION



ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME

6 of 44

1. Building & Process Utilities -- Flexibility

ISPE India Affiliate
Hyderabad Chapter
ENGINEERING PHARMACEUTICAL INNOVATION

Class A/B Class C Class D Class CNC

ENGINEERING PHARMACEUTICAL INNOVATION ISPE

Nov 8, 2013 ISPE VIZAG PROGRAMME 7 of 44

1. Building & Process Utilities -- Flexibility

ISPE India Affiliate
Hyderabad Chapter
ENGINEERING PHARMACEUTICAL INNOVATION

Class A/B Class C Class D Class CNC

ENGINEERING PHARMACEUTICAL INNOVATION ISPE

Nov 8, 2013 ISPE VIZAG PROGRAMME 8 of 44

1. Building & Process Utilities -- Personnel & Material Flow Excellence

1. Minimizing manual material flow distances


2. Unidirectional material flow:

Avoiding of any cross contamination by separating material flows by dedication of the corridors

- Corridor 1 : Raw material, primary packaging material, clean equipment
- Corridor 2 : Semi finished goods, dirty equipment

3. Gowning concepts which are simplifying / minimizing the gowning procedures and distances from the change rooms to the work places

1. Building & Process Utilities -- Personnel & Material Flow Excellence



Class A/B


Class C

Class D


Class CMC

1. Building & Process Utilities -- Personnel & Material Flow Excellence

Ground Floor (Street → D)




Class A/B
Class C
Class D
Class CNC




India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

Nov 8, 2013
ISPE VIZAG PROGRAMME

11 of 44



1. Building & Process Utilities -- Working Condition Excellence

1. Maximize daylight visibility for all permanent work places, including the possibility to control it in order to avoid negative impacts, e. g. ingress of heat or glazing (RABS & isolator)
2. Minimize noise emission for all permanent work places
3. Provide contemporary social rooms in short distance to the work places (change rooms, canteen, cafeteria)
4. **Better working conditions**
Higher staff motivation
Better product quality



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

Nov 8, 2013
ISPE VIZAG PROGRAMME

12 of 44


1. Building & Process Utilities -- Working Condition Excellence



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION



Noise insulation installed on a
vial washing machine



Maximize natural illumination
within production areas



Possibility to protect heat ingress by
using shades and double glass
walls with ventilation

ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME

13 of 44

1. Building & Process Utilities -- Working Condition Excellence



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

3. Provide contemporary social rooms in short distances to the work places (change rooms, canteen, cafeteria)



ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME

14 of 44

1. Building & Process Utilities -- Green Technology

Google search results for "green technology". The first result is "Environmental technology - Wikipedia, the free encyclopedia", which is circled in red. Other results include "Green Technology", "What is Green Technology?", "die Green Technology Staffing", "GreenTech Germany", and "Green Technology | Cleantech and Renewable Energy News and ...".

1. Building & Process Utilities -- Energy Efficiency




- **US Green Building Council**
LEED (Leadership in Energy and Environmental Design)
Rating:
Certified: 40-49 points
Silver: 50-59 points
Gold: 60-79 points
Platinum: 80-110 points
- Score system to measure the sustainability of a new building or a building after a major renovation in terms of the following aspects:
 - Site selection
 - Water consumption
 - Energy consumption
 - Protection of the earth atmosphere-
 - Choice of construction material
- Most frequent used (outside of the USA) in Asia

1. Building & Process Utilities -- Green Technology

1. Typical Measures used in Pharmaceutical Facilities are :

- Possibility of using renewable energies
- High efficient energy recovery for HVAC units
- Re-use of waste heat, mainly for pre-heating purposes
- Re-use of "clean" water (e. g. water from final rinse processes)
- Wind energy
- Photovoltaic System



ENGINEERING PHARMACEUTICAL INNOVATION

1. Building & Process Utilities -- Modular Facilities

NNE Pharmaplan standerized modular facility :

1. Pre-engineered production facility to decrease the timeline for implementation but allows customer specific configuration
2. Capable of being implemented as a new building or within an existing building
3. Build in flexibility with scale up possibility (clinical (500 l reactor), launch (1000 l reactor or market supply (up to 2000 l reactor)
4. Freedom to choose a variety of brands based on customer standards
5. Consequent use of single use technology, isolator technology and RTU components for fill & finish

ENGINEERING PHARMACEUTICAL INNOVATION

Contents



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

1. Building / Process Utilities

- Flexibility
- Personnel and material flow excellence
- Working condition excellence
- Green technology
- Modular facilities

2. Process Technology

- Cleanroom technology
- Ready to fill (RTF) primary containers
- Single Use Components

3. Some conclusions

ENGINEERING PHARMACEUTICAL INNOVATION




2. Process Technology -- Cleanroom Technology



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

State of the art 60 years ago...



ENGINEERING PHARMACEUTICAL INNOVATION



2. Process Technology -- Cleanroom Technology



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

State of the art today (RABS)...



ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME

21 of 44

2. Process Technology -- Cleanroom Technology



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

State of the art today (Isolator)...



ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME

22 of 44

2. Process Technology -- Cleanroom Technology



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

State of the art 2050...



ENGINEERING PHARMACEUTICAL INNOVATION



2. Process Technology -- Cleanroom Technology



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

Main comparison criteria for "RABS / isolator :

Criteria	RABS	Isolator	Remarks
Sterility Assurance Level	+ to ++*	++	*if room sterilisation installed
Operator protection	- to +*	++	*for closed RABS
Material and Personnel flow	-	+	
Investment costs	o	-	
Running costs	-	+	
Productivity	o to ++	-- to ++	depending on prod. portfolio
Regulatory compliance	+	+	
Industry trend	+	+	
Realization time	-	--	

--- = very bad (very high) - = bad (high) o = fair + = good (low) ++ = very good (very low)

ENGINEERING PHARMACEUTICAL INNOVATION



2. Process Technology -- Cleanroom Technology

Investment Costs:

- The number of manufacturers for class A isolators has increased in the past, it is not the usual three anymore... It is very likely that the competition will even increase in the future.
- The design of RABS is getting more and more sophisticated. Today RABS filling machines are placed in rooms which are capable of being VHP decontaminated which increases the investment significantly.
- Higher investment costs are often justified by lower running costs showing lower TCO.

2. Process Technology -- Cleanroom Technology


Investment costs (Example: Filling line for vials: Isolator vs. open RABS)

Description	Unit Price [Mio €]	Unit	RABS [amount]	Isolator [amount]	RABS [Mio €]	Isolator [Mio €]
Class D area	0,004	m²	620	650	2,5	2,6
Class A/B area	0,008	m²	60	0	0,5	0,0
Isolator class A	2,9	pcs	0	1	0,0	2,9
RABS system	0,4	pcs	1	0	0,4	0,0
Filling line	-	pcs	1	1	4,5	4,6
VHP passthrough	0,7	pcs	1	0	0,7	0,0
VHP room decontamination	0,9	pcs	1	0	0,9	0,0
Steam sterilizer	1,0	pcs	1	1	0,4	0,4
TOTAL					9,9	10,5

2. Process Technology -- Cleanroom Technology

Productivity:

- Isolators did always have the advantage in terms of productivity for big batches. A batch duration of 5 days for example is common practice.
- Isolators did always have the disadvantage if batch sizes are small and frequent format changes requiring an opening of the isolator with a time consuming VHP cycle. Today the situation has changed:



ENGINEERING PHARMACEUTICAL INNOVATION

2. Process Technology -- Cleanroom Technology

Regulatory Compliance:

- In the past the US FDA was more doubtful rather than supporting isolator technology. Since a couple of years the picture has changed completely. The FDA favors isolator technology:

Rick Friedman:

(Director, Division of Manufacturing & Product Quality, CDER, FDA)

Comments in 6/2009

"He would not put in conventional cleanrooms but in isolators and perhaps RABS (Restricted Access Barrier Systems)"

- Many multinational companies already have internal guidelines in place saying that isolator technology is the company standard for processes requiring class A. Any exception has to be specifically justified.

ENGINEERING PHARMACEUTICAL INNOVATION

2. Process Technology -- Cleanroom Technology

Summary:

- Isolator technology has improved a lot during the recent past years and there is still a huge potential to develop further particularly in combination with the following 3 upcoming technologies:
 1. Single use filling systems
 2. RTF primary containers and RTU closures (syringes and vials)
 3. Robotic technology

It will become more and more unlikely in the future not to decide for an isolator system compared to RABS setup, which brings me back to the question...

2. Process Technology -- Cleanroom Technology

State of the art for aseptic /fill & finish by 2025...

?

2. Process Technology -- RTF Primary Containers

1. Currently already a standard for liquid syringes
2. First supplier on the market which can deliver also RTF vials, others are already in the process of building up production capacities for this product and will introduce the product soon to the market.
3. The design / size of the RTF vials is very similar to the RTF syringes which will soon offer a new dimension of flexibility to the pharmaceutical manufacturers
4. Soon there will be Tray filling machines on the market which are able to fill and close syringes and vials (liquid & lyophilized) on a day to day routine without major format change

2. Process Technology -- RTF Primary Containers

Already available from Ompi (see below), others will follow soon...



2. Process Technology -- RTF Primary Containers

Advantages RTF Process

- **Product Quality**
No glass to glass contact during vial transport, de-pyrogenation & freeze drying
- **Investment Costs**
No washing machine, tunnel required, less complex equipment for loading and unloading of a freeze dryer required and smaller cleanroom required
- **Flexibility**
Possibility to process different primary container types and/or sizes on the same equipment with very short change over times

Disadvantages RTF Process:

- **Costs per Unit of the Primary Packaging Material**
Significant higher costs (vials / syringes)
- **Supply to the Market, Number of Suppliers**
Supply to market just started for vials, machines for dual use in the development phase
- **Equipment Utilization**
Approx. 30% less utilization within a freeze dryer

2. Process Technology -- Cleanroom Technology



SA25 RAPTOR Aseptic Filling Workcell



SA25 RAPTOR Aseptic Filling Workcell is a fully integrated and isolated filling system for the production of sterile injectables.

"Zero Intervention" ensures product integrity by eliminating aseptic interventions and aseptic assembly.

Designed for clinical & small batch operations, the SA25 RAPTOR is ideal for potent compounds, biologics, vaccines and personalized medicine.

Specifications

Speed	25upm (3mL)
Accuracy	±10%
Interior Classification	ISO 5
Exterior Classification	ISO 8
Space Requirements	< 55m ³ (600ft ³)

Features

Full 316L Stainless Interior & Robotics
No Change Parts**
Washdown & CIP Ready
Vapor Peroxide and ClO₂ Gas Compatible
Zero Intervention Technology
Disposable Fill Path
Automated EM Monitoring

* Pictures courtesy Vanrx PharmaSystems Inc.


2. Process Technology -- RTF Primary Containers

Case Study: Small Scale Production Equipment for a Company in Malaysia

- Liquid and freeze dried vials
- Performance up to 1.000 units per hour
- Design capable of handling products up to a OEB 1-20µg/m³
- Investment for the following equipment less than 4 Mio Euro (5 Mio. US \$)
 - 2 Isolators (Grade A)
 - 1 VHP pass box
 - 1 FD (5m² shelf area)
 - 1 Filling and closing equipment
 - 1 Capping machine
 - 1 Isolator (Grade C)
 - 1 Outside washing machine

→ A bulk vial line would be min. 6 Mio. Euro (7.5 Mio US \$)

2. Process Technology -- RTF Primary Containers



Control unit
Operator panel,
Recorder etc.

VHP lock

Working Chamber 1
Tray unpacking and opening
Vial filling and stoppering


Working Chamber 2
Lyophilizer loading and unloading
Vial singalizing for capping

* Pictures courtesy Skan AG

2. Process Technology -- RTF Primary Containers



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION



ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME


37 of 44

2. Process Technology -- RTF Primary Containers



India Affiliate
Hyderabad Chapter
ENGINEERING
PHARMACEUTICAL
INNOVATION

Robotic system installed in the back wall of an isolator



* Pictures courtesy Skan AG

ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME


38 of 44

2. Process Technology -- Single Use Components

General Advantages

- Saving utilities (CIP/SIP)
- Saving investment costs
- Avoiding cleaning validation
- Faster filling machine set up between two batches / products (less filling machine downtime, especially in combination with an isolator)
- Less product loss at batch end

Less important



Very important

ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013


ISPE VIZAG PROGRAMME

39 of 44

2. Process Technology -- Single Use Components

Rolling diaphragm pump or peristaltic pump

PreVAS Components



* Pictures courtesy Robert Bosch GmbH

ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME

40 of 44

2. Process Technology -- Single Use Components

Component	Options	Picture
System Connector	Quick Disconnect Tri-Clamp Adapter Sterile Connector Other	
Bag Assembly	None 2 Liter 5 Liter 10 Liter	
Manifold Configuration	In-line Split Line Blind Valve Recirculation Loop	
Number of Pumps/Needles	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	
Pumping System Type	Peristaltic Dual Line 60cc RCP 50cc RCP	
Needles (Inside Diameter)	1.2mm 1.5mm 2.1mm 3.0mm 3.8mm 4.6mm 5.2mm	
Packaging Requirements	Double Bagged Triple Bagged RTP Port for Isolator/RABS	

* Picture courtesy Robert Bosch GmbH

Advantages:

- Pre qualified construction kit which reduces costs and timelines for the user
- Reduced costs due to standardization
- Better regulatory acceptance

Disadvantages:

- Tailor made for Bosch filling machines
- Dependent on one supplier
- Customer specific changes in the system will be very limited

ENGINEERING PHARMACEUTICAL INNOVATION

Contents

- Building / Process Utilities**
 - Flexibility
 - Personnel and material flow excellence
 - Working condition excellence
 - Green technology
 - Modular facilities
- Process Technology**
 - Cleanroom technology
 - Ready to fill (RTF) primary containers
 - Single Use Components
- Some conclusions**

ENGINEERING PHARMACEUTICAL INNOVATION

3. Some Conclusions -- For further Questions



- **Isolator Technology**
Will develop further in the future and will dominate the aseptic fill & finish industry in the future
- **Single Use Filling Systems**
Peristaltic pump systems are often the preferred system for Biopharmaceuticals, standardized (pre-validated) single use filling systems are entering the market more and more
- **Flexibility**
Next generation of RTF filling machine will be able to process syringes **and** vials with very short downtime for change over
- **Robots / Handling systems**
Individual positive transport, avoidance of glass to glass contact, minimizing rejects and glass breakage rate and very flexible (fast) format change

The combination of all 4 topics as a package provides significant advantages in terms of product quality, productivity and flexibility !

ENGINEERING PHARMACEUTICAL INNOVATION



Nov 8, 2013

ISPE VIZAG PROGRAMME

43 of 44

Thankyou for Your Attention



Narendra Prasad
NNE Pharmaplan India Limited
Phone : +91 – 98101 601 36
Email : NarP@nnepharmaplan.com



ENGINEERING PHARMACEUTICAL INNOVATION

